Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks
<b>(1) Background:</b> Prurigo nodularis (PN) is a persistent and inflammatory dermatological condition characterized by chronic itching and the formation of hardened nodules, significantly impacting the affected individuals’ quality of life and psychological well-being. The management o...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/13/3/878 |
| _version_ | 1797318533878644736 |
|---|---|
| author | Claudia Paganini Marina Talamonti Virginia Maffei Cosimo Di Raimondo Luca Bianchi Marco Galluzzo |
| author_facet | Claudia Paganini Marina Talamonti Virginia Maffei Cosimo Di Raimondo Luca Bianchi Marco Galluzzo |
| author_sort | Claudia Paganini |
| collection | DOAJ |
| description | <b>(1) Background:</b> Prurigo nodularis (PN) is a persistent and inflammatory dermatological condition characterized by chronic itching and the formation of hardened nodules, significantly impacting the affected individuals’ quality of life and psychological well-being. The management of PN poses challenges due to the limited efficacy and undesirable side effects associated with current interventions. <b>(2) Methods:</b> This article examines sixteen patients affected by PN treated with dupilumab, a fully human monoclonal antibody targeting interleukin IL-4 and IL-13 signaling. This involves a retrospective descriptive statistical analysis. <b>(3) Results and (4) Conclusions:</b> In all patients, dupilumab proves to be an effective drug in achieving disease clearance, as indicated by all the parameters considered as assessed by both physicians and patients at each evaluation point (Week 6, Week 16, Week 32, Week 52, Week 68, and Week 84), in comparison to the initial baseline. |
| first_indexed | 2024-03-08T03:53:49Z |
| format | Article |
| id | doaj.art-86922b400a484ba38a89a255717a850a |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T03:53:49Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-86922b400a484ba38a89a255717a850a2024-02-09T15:16:37ZengMDPI AGJournal of Clinical Medicine2077-03832024-02-0113387810.3390/jcm13030878Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 WeeksClaudia Paganini0Marina Talamonti1Virginia Maffei2Cosimo Di Raimondo3Luca Bianchi4Marco Galluzzo5Department of Systems Medicine, University of Rome “Tor Vergata”, 00133 Rome, ItalyDermatology Unit, Fondazione Policlinico Tor Vergata, 00133 Rome, ItalyDepartment of Systems Medicine, University of Rome “Tor Vergata”, 00133 Rome, ItalyDermatology Unit, Fondazione Policlinico Tor Vergata, 00133 Rome, ItalyDepartment of Systems Medicine, University of Rome “Tor Vergata”, 00133 Rome, ItalyDepartment of Systems Medicine, University of Rome “Tor Vergata”, 00133 Rome, Italy<b>(1) Background:</b> Prurigo nodularis (PN) is a persistent and inflammatory dermatological condition characterized by chronic itching and the formation of hardened nodules, significantly impacting the affected individuals’ quality of life and psychological well-being. The management of PN poses challenges due to the limited efficacy and undesirable side effects associated with current interventions. <b>(2) Methods:</b> This article examines sixteen patients affected by PN treated with dupilumab, a fully human monoclonal antibody targeting interleukin IL-4 and IL-13 signaling. This involves a retrospective descriptive statistical analysis. <b>(3) Results and (4) Conclusions:</b> In all patients, dupilumab proves to be an effective drug in achieving disease clearance, as indicated by all the parameters considered as assessed by both physicians and patients at each evaluation point (Week 6, Week 16, Week 32, Week 52, Week 68, and Week 84), in comparison to the initial baseline.https://www.mdpi.com/2077-0383/13/3/878prurigo nodularisdupilumabatopic dermatitis |
| spellingShingle | Claudia Paganini Marina Talamonti Virginia Maffei Cosimo Di Raimondo Luca Bianchi Marco Galluzzo Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks Journal of Clinical Medicine prurigo nodularis dupilumab atopic dermatitis |
| title | Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks |
| title_full | Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks |
| title_fullStr | Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks |
| title_full_unstemmed | Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks |
| title_short | Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks |
| title_sort | dupilumab for treatment of prurigo nodularis real life effectiveness for up to 84 weeks |
| topic | prurigo nodularis dupilumab atopic dermatitis |
| url | https://www.mdpi.com/2077-0383/13/3/878 |
| work_keys_str_mv | AT claudiapaganini dupilumabfortreatmentofprurigonodularisreallifeeffectivenessforupto84weeks AT marinatalamonti dupilumabfortreatmentofprurigonodularisreallifeeffectivenessforupto84weeks AT virginiamaffei dupilumabfortreatmentofprurigonodularisreallifeeffectivenessforupto84weeks AT cosimodiraimondo dupilumabfortreatmentofprurigonodularisreallifeeffectivenessforupto84weeks AT lucabianchi dupilumabfortreatmentofprurigonodularisreallifeeffectivenessforupto84weeks AT marcogalluzzo dupilumabfortreatmentofprurigonodularisreallifeeffectivenessforupto84weeks |